Hudson Bay Capital Management
TEVA icon

Hudson Bay Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Hudson Bay Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-495,000
Closed -$15.4M – 1594
2025
Q4 		$15.4M Buy
+495,000
New +$12.2M 0.05% 265
2013
Q4 		– Sell
-100,000
Closed -$3.78M – 182
2013
Q3 		$3.78M Buy
+100,000
New +$3.9M 0.14% 97

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hudson Bay Capital Management's TEVA Position: Q1 2026 in Review

Hudson Bay Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 75,000 shares — an estimated $2.34M sold.

Hudson Bay Capital Management first reported a position in TEVA in Q1 2014 and held it in 11 quarters. The position peaked at $25M in Q1 2014. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Hudson Bay Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 75,000 Teva Pharmaceuticals shares in Q1 2026, an estimated $2.34M.
  • Hudson Bay Capital Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 11 quarters.
  • Hudson Bay Capital Management's Teva Pharmaceuticals position peaked at $25M in Q1 2014.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.